| Identification | More | [Name]
TOSUFLOXACIN TOSILATE | [CAS]
100490-36-6 | [Synonyms]
TOSUFLOXACIN
TOSUFLOXACIN TOSILATE
TOSUFLOXACIN TOSYLATE
1,8-naphthyridine-3-carboxylicacid,1,4-dihydro-7-(3-amino-1-pyrrolidinyl)-1-(
4-difluorophenyl)-6-fluoro-4-oxo-
a61827
a67107
abbott61827
1-(2,4-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-aminopyrrolidin-1-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid
1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-(9CI)
(+)-7-(3-Amino-1-pyrrolidinyl)-6-fluoro-1-(2，4-difluo-rophenyl)-1，4-dihydrcr-4-oxo-1，8-naphthyridine-3-carboxyli cacid
A-60969
Ozex
Toskisasin
7-(3-Aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
7-(3-Aminopyrrolizino)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
TFLX | [Molecular Formula]
C26H23F3N4O6S | [MDL Number]
MFCD01711971 | [Molecular Weight]
576.54 | [MOL File]
100490-36-6.mol |
| Hazard Information | Back Directory | [Uses]
Tosufloxacin Tosilate (CAS# 100490-36-6) was identified in a Haemophilus influenza clone ST422. | [Definition]
ChEBI: 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid is a 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively. It is a 1,8-naphthyridine derivative, an amino acid, a monocarboxylic acid, an organofluorine compound, an aminopyrrolidine, a tertiary amino compound, a primary amino compound and a quinolone antibiotic. It is a conjugate base of a 1-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]pyrrolidin-3-aminium. | [in vivo]
Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo[2]. | Animal Model: | Male Slc:ICR mice infected with S. aureus[2] | | Dosage: | 1.27-2.15 mg/kg | | Administration: | Oral gavage; 1.27-2.15 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 1.62 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.0125 μg/mL. |
| Animal Model: | Male Slc:ICR mice infected with E. coli[2] | | Dosage: | 0.16-0.30 mg/kg | | Administration: | Oral gavage; 0.16-0.30 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 0.22 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.0125 μg/mL. |
| Animal Model: | Male Slc:ICR mice infected with P. aeruginosa[2] | | Dosage: | 7.66-13.39 mg/kg | | Administration: | Oral gavage; 7.66-13.39 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 10.13 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.78 μg/mL. |
| [IC 50]
Quinolone |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
guoyungurui
|
| Tel: |
18162595016; 18162595016 |
| Website: |
https://www.chemicalbook.com/supplier/25521782/ |
|